5-aminopyrazoles useful as tyrosine kinase inhibitors
申请人:Celltech Therapeutics Ltd.
公开号:US05922741A1
公开(公告)日:1999-07-13
Compounds of general formula (1) are described: ##STR1## wherein Ar is an optionally substituted aromatic or heteroaromatic group; X.sup.1 is an oxygen or sulphur atom; R.sup.1 is a hydrogen atom or a methyl group; R.sup.2 is a hydrogen atom or a group --Alk.sup.1 or --X.sup.2 Alk.sup.1 where Alk.sup.1 is an optionally substituted aliphatic or heteroaliphatic group and X.sup.2 is a --C(O)--, --C(S)--, or --S(O).sub.n group where n is an integer 1 or 2; R.sup.3 is a hydrogen atom or a group --Alk.sup.2, \x9bwhere Alk.sup.2 is as defined for Alk.sup.1 !, --X.sup.2 Alk.sup.2, --Ar.sup.1 \x9bwhere Ar.sup.1 is an optionally substituted aromatic or heteroaromatic group!, --Alk.sup.2 Ar.sup.1, or --X.sup.2 Alk.sup.2 Ar.sup.1 ; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective inhibitors of the protein tyrosine kinase p56.sup.lck and are of use in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate p56.sup.lck activity is believed to have a role.